New England Journal of Medicine· 2018Q1· Clinical trial
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- 2,348citations
- Q1SCImago
- 2018year
Short summary
In previously treated patients with advanced liver cancer, cabozantinib significantly improved overall survival by 2.2 months and progression-free survival by 3.3 months compared to placebo.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hepatology
HepatologyMedicine